Nuvectra Achieves 1,000th Algovita® SCS System Implantation in U.S.

[junkie-button url=”” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]

The Algovita SCS System is a powerful and versatile spinal cord stimulation system that utilizes the Company’s patent-protected stretchable lead technology and includes the smallest patient controller on the market.

“Nuvectra is both excited and proud to celebrate the company’s 1,000th U.S. implant with Dr. Giancarlo Barolat and his team in Denver, said Scott Drees, CEO of Nuvectra. “Achieving the 1,000th Algovita implant milestone marks a significant commercial achievement for Nuvectra, reflecting our positive momentum in the SCS market and the progress we have made in building our commercial team. We continue to receive positive physician and patient feedback, and we remain confident in our ability to further grow our market share in an expanding SCS market as we continue to raise awareness of the Algovita SCS system.”

Dr. Barolat responded, “With Alogvita, I am able to offer my patients effective non-opioid pain relief with a highly sophisticated SCS system that offers four unique stimulation modes for long-term chronic pain control. In my experience, the Algovita system is easy to implant and program, and Algovita patients achieve significant and sustained reductions in pain with an overall improvement in function and quality of life.”

Dr. Barolat is an internationally-recognized expert in neurostimulation therapy for chronic pain and a pioneer of spinal cord stimulation for spasticity and pain management.  He has four decades of experience implanting more than 9,000 devices encompassing almost every neurostimulation application in the market, including pain, paralysis, headaches, spasticity, dystonia, Parkinson’s disease, epilepsy and bladder dysfunction.

Since June 2005, Dr. Barolat has practiced neurosurgery and neuromodulation in Denver, Colorado in affiliation with Presbyterian/St. Luke’s Medical Center. Dr. Barolat completed medical school and his residency in Neurosurgery at the University of Torino, Italy.  He holds fellowships in Functional Neurosurgery and Neurostimulation and Spinal Cord Injury and is board certified by the American and Italian Boards of Neurosurgery. Dr. Barolat served two consecutive terms as President of the International Neuromodulation Society, where he currently serves as Director-at-Large and was a Founding Member of the American Neuromodulation Society. He received a Lifetime Achievement Award from the American Association of Neurological Surgery in 2010 and another from the North American Neuromodulation Society in 2013.